EW monthly performance report
Monthly EW research: returns, drawdown, relative strength, seasonality, and key stats.
EW monthly report
—
Key takeaways
- Edwards Lifesciences (EW) closed August 2026 at $88.97, up 3.37% for the month and +12.28% over the trailing 12 months.
- Year-to-date, EW is +4.36%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +6.16% versus its 200-day moving average ($83.81), a bullish technical signal.
- Over the past three years, EW has underperformed the S&P 500 by −60.44%, with a relative strength index reading of 65.2.
- Win rate over the trailing 39 months stands at 66.7% — 26 positive months versus 13 negative months.
Edwards Lifesciences ended August 2026 at $88.97, posting a monthly return of +3.37%. The S&P 500 returned +3.05% over the same window, leaving relative performance at +0.32%.
The current quarter stands at −4.93% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +6.16% versus the 200-day moving average ($83.81).
Year-to-date, EW is +4.36% against SPY +12.89%, a gap of −8.52%. The stock is currently −7.60% below its 52-week high, with maximum 3-year drawdown at −37.53%.
| Period | EW | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.70% | −0.20% | −0.50% |
| 1 Week | +6.32% | +3.90% | +2.42% |
| 1 Month | +3.37% | +3.05% | +0.32% |
| 3 Months | +6.55% | +7.11% | −0.56% |
| 6 Months |